Nitoman (Tetrabenazine)

Tetrabenazine blocks the vesicular monoamine transporter 2 (VMAT2) in nerve terminals, preventing dopamine and other monoamines from being stored in synaptic vesicles. This depletion lowers dopaminergic signaling in the brain, thereby diminishing the excessive motor activity that characterizes chorea and dyskinesia.

The dosage of Nitoman is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the starting dose, titration schedule, and maximum daily amount, following local regulatory guidelines and clinical judgment.

Safety data for tetrabenazine in pregnancy and lactation are limited. It is generally classified as contraindicated or to be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nitoman, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nitoman (tetrabenazine) is the first‑generation VMAT2 inhibitor, whereas deutetrabenazine (Austedo) is a newer formulation with a longer half‑life and potentially fewer dosing adjustments. Both share the same mechanism, but deutetrabenazine may offer smoother plasma levels, reducing the frequency of dose titration for some patients.

Nitoman tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it away from direct sunlight or heat sources to maintain potency throughout its shelf life.

Nitoman is taken orally as a tablet, usually with a full glass of water. The prescriber will advise whether the medication should be taken with food or on an empty stomach, and the dosing schedule (once daily or divided doses) will be individualized.

The most critical safety concerns include the potential for severe depression, suicidal thoughts or behavior, and cardiac QT‑interval prolongation, which can lead to arrhythmias. Patients should be monitored closely for mood changes and cardiac symptoms, and any concerning signs require immediate medical evaluation.

Nitoman is contraindicated in individuals with known QT prolongation, severe hepatic impairment, or those currently receiving monoamine oxidase (MAO) inhibitors. Caution is also advised for patients with a history of depression, suicidal ideation, or significant cardiac disease, and it should be avoided unless benefits outweigh risks.